Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

88.82% of the stock is currently owned by institutional investors. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...